Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AKBANASDAQ:AVXLNASDAQ:NBTXNASDAQ:NRIX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAKBAAkebia Therapeutics$2.86+1.1%$2.20$0.80▼$2.97$751.14M0.882.91 million shs3.11 million shsAVXLAnavex Life Sciences$7.53-1.8%$8.75$3.51▼$14.44$642.85M0.821.23 million shs666,574 shsNBTXNanobiotix$3.80+4.4%$3.46$2.76▼$7.29$172.45M0.2615,503 shs3,605 shsNRIXNurix Therapeutics$9.72-2.7%$10.67$8.18▼$29.56$741.01M2.23873,228 shs401,505 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAKBAAkebia Therapeutics0.00%+9.58%+25.44%+58.89%+160.00%AVXLAnavex Life Sciences0.00%-9.50%-20.32%-9.82%+67.33%NBTXNanobiotix0.00%-2.21%+15.12%+1.31%-38.92%NRIXNurix Therapeutics0.00%+1.67%-15.63%-42.38%-39.66%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAKBAAkebia Therapeutics4.1931 of 5 stars4.62.00.04.03.00.00.6AVXLAnavex Life Sciences3.7544 of 5 stars3.71.00.04.72.80.80.6NBTXNanobiotix1.66 of 5 stars3.35.00.00.00.00.00.6NRIXNurix Therapeutics2.4103 of 5 stars4.41.00.00.03.60.80.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAKBAAkebia Therapeutics 3.20Buy$6.63131.64% UpsideAVXLAnavex Life Sciences 3.33Buy$44.00484.33% UpsideNBTXNanobiotix 2.50Moderate Buy$8.00110.58% UpsideNRIXNurix Therapeutics 2.84Moderate Buy$30.44213.21% UpsideCurrent Analyst Ratings BreakdownLatest NBTX, AKBA, NRIX, and AVXL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/29/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$27.00 ➝ $27.004/28/2025AKBAAkebia TherapeuticsLeerink PartnrsSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025AKBAAkebia TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$7.004/9/2025NRIXNurix TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$32.00 ➝ $25.004/9/2025NRIXNurix TherapeuticsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$36.00 ➝ $35.004/9/2025NRIXNurix TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $27.004/7/2025AVXLAnavex Life SciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$42.00 ➝ $42.004/7/2025AVXLAnavex Life SciencesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$46.00 ➝ $46.004/4/2025AKBAAkebia TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$7.50 ➝ $7.504/4/2025NBTXNanobiotixGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$12.00 ➝ $8.004/2/2025NRIXNurix TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$36.00 ➝ $36.00(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAKBAAkebia Therapeutics$184.91M4.06N/AN/A($0.16) per share-17.88AVXLAnavex Life SciencesN/AN/AN/AN/A$1.42 per shareN/ANBTXNanobiotix-$11.61M-15.42N/AN/A($0.04) per share-94.98NRIXNurix Therapeutics$56.42M13.13N/AN/A$7.44 per share1.31Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAKBAAkebia Therapeutics-$51.92M-$0.21N/AN/AN/A-27.07%N/A-20.57%N/AAVXLAnavex Life Sciences-$43M-$0.55N/AN/AN/AN/A-37.50%-34.08%8/5/2025 (Estimated)NBTXNanobiotix-$42.97MN/A0.00N/AN/AN/AN/AN/AN/ANRIXNurix Therapeutics-$193.57M-$2.80N/AN/AN/A-354.85%-53.65%-38.59%7/10/2025 (Estimated)Latest NBTX, AKBA, NRIX, and AVXL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q2 2025AVXLAnavex Life Sciences-$0.16-$0.13+$0.03-$0.13N/AN/A5/8/2025Q1 2025AKBAAkebia Therapeutics-$0.03$0.03+$0.06$0.03$44.88 million$57.34 million4/8/2025Q1 2025NRIXNurix Therapeutics-$0.72-$0.67+$0.05-$0.67$12.78 million$18.45 million3/13/2025Q4 2024AKBAAkebia Therapeutics-$0.05-$0.10-$0.05-$0.10$37.36 million$46.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAKBAAkebia TherapeuticsN/AN/AN/AN/AN/AAVXLAnavex Life SciencesN/AN/AN/AN/AN/ANBTXNanobiotixN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAKBAAkebia TherapeuticsN/A1.521.21AVXLAnavex Life SciencesN/A9.459.45NBTXNanobiotixN/A1.42N/ANRIXNurix TherapeuticsN/A6.466.46Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAKBAAkebia Therapeutics33.92%AVXLAnavex Life Sciences31.55%NBTXNanobiotix38.81%NRIXNurix TherapeuticsN/AInsider OwnershipCompanyInsider OwnershipAKBAAkebia Therapeutics3.00%AVXLAnavex Life Sciences11.40%NBTXNanobiotix3.45%NRIXNurix Therapeutics7.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAKBAAkebia Therapeutics430262.64 million209.24 millionOptionableAVXLAnavex Life Sciences4085.37 million75.71 millionOptionableNBTXNanobiotix10047.13 million45.51 millionNot OptionableNRIXNurix Therapeutics30076.24 million70.42 millionOptionableNBTX, AKBA, NRIX, and AVXL HeadlinesRecent News About These CompaniesTwinbeech Capital LP Sells 35,683 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 25 at 4:33 AM | marketbeat.comD. E. Shaw & Co. Inc. Acquires 40,001 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 23 at 3:43 AM | marketbeat.comNurix Therapeutics reports stockholder voting resultsMay 21, 2025 | uk.investing.comVelan Capital Investment Management LP Invests $1.84 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 21, 2025 | marketbeat.comVestal Point Capital LP Acquires 60,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 21, 2025 | marketbeat.comSoleus Capital Management L.P. Raises Stock Holdings in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 21, 2025 | marketbeat.comPoint72 Asset Management L.P. Takes $16.45 Million Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 20, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Sold by Deutsche Bank AGMay 19, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Shares Acquired by Northern Trust CorpMay 19, 2025 | marketbeat.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives $30.44 Average PT from BrokeragesMay 19, 2025 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Given Average Recommendation of "Moderate Buy" by AnalystsMay 18, 2025 | marketbeat.com229,369 Shares in Nurix Therapeutics, Inc. (NASDAQ:NRIX) Acquired by Jacobs Levy Equity Management Inc.May 17, 2025 | marketbeat.comNurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comParkman Healthcare Partners LLC Purchases 93,201 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 16, 2025 | marketbeat.comPatient Square Capital LP Acquires 120,507 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 16, 2025 | marketbeat.comEnsign Peak Advisors Inc Increases Position in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 16, 2025 | marketbeat.comNurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare ConferenceMay 15, 2025 | globenewswire.comNurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant LymphomaMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Acquires 50,000 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 14, 2025 | marketbeat.comCubist Systematic Strategies LLC Invests $2.34 Million in Nurix Therapeutics, Inc. (NASDAQ:NRIX)May 14, 2025 | marketbeat.comWhy Nurix Therapeutics (NRIX) Is Among the Best Low Priced Biotech Stocks to Buy NowMay 13, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeNBTX, AKBA, NRIX, and AVXL Company DescriptionsAkebia Therapeutics NASDAQ:AKBA$2.86 +0.03 (+1.06%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.86 0.00 (-0.03%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent patients. It offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. The company's product pipeline includes AKB-9090, a drug targeting critical-care indications; and AKB-10108, a drug targeting conditions related to premature birth. It has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Anavex Life Sciences NASDAQ:AVXL$7.53 -0.14 (-1.83%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$7.54 +0.00 (+0.07%) As of 05/23/2025 07:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.Nanobiotix NASDAQ:NBTX$3.80 +0.16 (+4.37%) Closing price 05/23/2025 03:49 PM EasternExtended Trading$3.80 +0.00 (+0.03%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is headquartered in Paris, France.Nurix Therapeutics NASDAQ:NRIX$9.72 -0.27 (-2.70%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$9.72 -0.01 (-0.05%) As of 05/23/2025 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Alphabet Stock Lags—But Waymo May Be Its Hidden Driver Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
